Hypothesis

Low‑dose rapamycin mimics ancestral scarcity, activating autophagy and reducing protein synthesis, but doesn't remove existing senescent cells or their inflammatory secretions. Meanwhile, NRF2 activators such as sulforaphane suppress the senescence‑associated secretory phenotype (SASP) without killing cells, thereby lowering the tissue‑damage feedback loop that drives aging. We hypothesize that simultaneous, low‑dose administration of rapamycin and an NRF2 activator will produce a synergistic extension of mouse lifespan that exceeds the sum of each monotherapy, because rapamycin slows the generation of new damage while NRF2 activation neutralizes the harmful signaling of already‑accumulated senescent cells, allowing immune surveillance to clear them more efficiently.

Testable Predictions

1. Lifespan – Male and female C57BL/6 mice aged 20 months will receive: (a) vehicle, (b) rapamycin (8 ppm diet), (c) sulforaphane (30 mg/kg diet), (d) low‑dose rapamycin + sulforaphane (half the monotherapy doses). Median lifespan of the combination group will be >15 % longer than controls, whereas each monotherapy will extend lifespan by ≤8 % (based on prior rapamycin data).

2. Senescent‑cell burden – Quantification of p16Ink4a‑positive cells in liver, kidney and adipose tissue at 30 months will show a greater than additive reduction in the combination group relative to monotherapies, indicating enhanced clearance.

3. SASP attenuation – Plasma levels of IL‑6, CXCL1 and MMP‑3 will be lowest in the combination group, reflecting stronger suppression of the inflammatory secretome than either agent alone.

4. Autophagy flux – LC3‑II/I ratios and p62 degradation in muscle will be elevated in all treatment groups, confirming that mTOR inhibition is engaged, but only the combination will show restored lysosomal activity (measured by cathepsin B activity) indicative of improved waste removal.

5. Healthspan – Frailty index, grip strength and treadmill endurance will be significantly better in the combination group at 28 months, with a statistically significant interaction term in two‑way ANOVA (p < 0.05).

Mechanistic Rationale

Rapamycin‑driven AMPK activation lowers mTORC1 signaling, which shifts cellular metabolism toward catabolism and promotes autophagy. This reduces the load of damaged proteins and organelles, slowing the formation of new senescent cells. NRF2 activation drives transcription of antioxidant and detoxification genes (e.g., HO‑1, NQO1) and directly inhibits NF‑κB‑mediated transcription of SASP cytokines. By dampening SASP, the local inflammatory milieu that reinforces senescence and impairs macrophage phagocytosis is alleviated, thereby increasing the efficiency of immune‑mediated senescent‑cell clearance. The combination thus couples a “slow‑damage” strategy with a “damage‑neutralizing” strategy, creating a condition where the existing senescent burden can be cleared rather than merely tolerated.

Falsifiability

If the combination does not produce a lifespan extension greater than the additive effect of the two monotherapies, or if senescent‑cell burden and SASP markers are not significantly lower than in the monotherapy groups, the hypothesis will be refuted. Likewise, absence of improved lysosomal activity or healthspan benefits despite molecular target engagement would challenge the proposed mechanistic link.

References (integrated)

[1] https://www.fightaging.org/archives/2023/05/reviewing-mtor-inhibition-as-a-pharmacological-strategy-to-modestly-slow-aging/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6925080/ [3] https://doi.org/10.1111/acel.12445 [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC9467395/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC12456441/ [6] https://doi.org/10.1016/j.freeradbiomed.2015.02.025